TTX-332 TRANSPLANT DELAYED GRAFT FUNCTION (DGF)

Healthcare leaders are stepping up efforts to diagnose and treat Acute Kidney Injury (AKI). The National Kidney Foundation reports that AKI affects 20% of all hospitalized patients and more than 45% of patients in a critical care setting. AKI, by some counts, has a 50% mortality rate, according to a study published last year in Critical Care Research and Practice. (Source: Acute Kidney Injury Gets New Focus, HealthLeaders Media, August 28, 2014)

"We're dealing with sicker and sicker older patients who are getting surgery that we never had dreamed of before," he says. "That puts them at risk for this." Stanley Goldfarb, MD—a professor of medicine at the Hospital of the University of Pennsylvania in Philadelphia.

Promising Therapeutic Strategy

Nur77 and its family members Nurr1 and Nor-1 are inducible orphan nuclear receptors that orchestrate cellular responses to diverse extracellular signals. Nur77 promotes epithelial apoptosis after ischemia-reperfusion injury, and TTX-332–mediated inhibition of Nur77 expression is a promising therapeutic strategy for the prevention of AKI.

CONSEQUENCES

The consequences of ignoring signs of AKI are significant for hospitals, says Ravindra L. Mehta, MD, associate chair for clinical research in the department of medicine and director of the acute dialysis program for the University of California San Diego Health System and panel member of the Acute Kidney Injury Network, noting that changes in creatinine are associated with increased resource utilization, including length of stay, long-term and short-term mortality, and re-hospitalization rates.

MeEt Us

View our upcoming events

View All Events